Eric Wang, Ph.D.

Eric Wang's Research Focus

Cancer, Immune Disorders, Molecular Biology
Adaptive Immunity, Cancer Biology, Disease Therapies, Tumor Microenvironment, Cell Biology
Chemical Biology, Drug Discovery

Dysregulation of transcriptional circuits is a common hallmark of disease, and in particular is found in both tumor and host immune cells in cancer. Eric’s lab is focusing on developing and using chemical tools to modulate the activity of key transcriptional regulators of both tumor cells and host immune cells, with a long-term goal of identifying new therapeutic approaches.

Eric Wang's Bio

Eric has a broad background in chemical biology, with specific training and expertise in kinase inhibitors and targeted protein degradation, an emerging modality in which small molecules recruit E3 ligase complexes to target proteins to induce their ubiquitination and subsequent proteasomal degradation. He also has experience in pharmacological modulation of immune cells to improve anti-tumor immunity.
He received his Ph.D. from the University of California San Francisco and postdoctoral training at the Dana-Farber Cancer Institute.


Education and Training

2021: Postdoctoral Fellow, Dana-Farber Cancer Institute / Harvard Medical School
2009: Ph.D., University of California San Francisco, 2015 B.S., Duke University



Damon Runyon Cancer Research Foundation Fellowship

general accessory


CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK

Cancer Discov 2018 Feb ;8(2):216-233

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS

Blood 2019 Feb 28 ;133(9):952-961

Acute pharmacological degradation of Helios destabilizes regulatory T cells.

Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES

Nat Chem Biol 2021 Jun ;17(6):711-717

Show All Select Publications

PSGL-1 attenuates early TCR signaling to suppress CD8(+) T cell progenitor differentiation and elicit terminal CD8(+) T cell exhaustion.

Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, Lin M, Henriquez ML, Roy S, Seo H, Lei X, Wang ES, Chow S, Tinoco R, Daniels GA, Yip K, Campos AR, Yin J, Adams PD, Rao A, Bradley LM

Cell Rep 2023 Apr 26 ;42(5):112436

Corrigendum: Efficient protoplast regeneration protocol and CRISPR/Cas9-mediated editing of glucosinolate transporter (GTR) genes in rapeseed (Brassica napus L.).

Li X, Sandgrind S, Moss O, Guan R, Ivarson E, Wang ES, Kanagarajan S, Zhu LH

Front Plant Sci 2023 ;14:1183684

Corrigendum: Improved fatty acid composition of field cress (Lepidium campestre) by CRISPR/Cas9-mediated genome editing.

Sandgrind S, Li X, Ivarson E, Wang ES, Guan R, Kanagarajan S, Zhu LH

Front Plant Sci 2023 ;14:1183817

Shining light on reprogramming Tregs for cancer therapy.

Wang ES, Gray NS

Cell Chem Biol 2023 Mar 16 ;30(3):231-233

MDM2 and BCL-2: to p53 or not to p53?

Wang ES

Blood 2023 Mar 16 ;141(11):1237-1238

Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader.

Teng M, Jiang J, Wang ES, Geng Q, Toenjes ST, Donovan KA, Mageed N, Yue H, Nowak RP, Wang J, Manz TD, Fischer ES, Cantley LC, Gray NS

Angew Chem Int Ed Engl 2023 Apr 24 ;62(18):e202302364

Show All Publications